Lipids for use in lipid nanoparticle formulations

A compound having the following structure (I):

• or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
• L1 is —NRaC(═O)R1 or —C(═O)NRbRc;
• L2 is —NRdC(═O)R2 or —C(═O)NReRf;
• G1 and G2 are each independently C3-C12 alkylene or C3-C12 alkenylene;
• G3 is C1-C24 alkylene or C2-C24 alkenylene;
• Ra, Rb, Rd and Re are each independently H, C1-C16 alkyl or C2-C16 alkenyl;
• Rc and Rf are each independently C1-C16 alkyl or C2-C16 alkenyl;
• R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl;
• R3 is H, —OH, CN, —C(═O)N(R4)R5;
• —N(R4)C(═O)R5;
• —N(R4)C(═O)OR5;
• —C(═O)OR6, —OC(═O)R6, —OR7, heteroaryl or aryl;
• R4 and R5 are each independently is H, C1-C12 alkyl, C3-C6 cycloalkyl or C3-C6 cycloalkenyl, or R4 and R5, together with the nitrogen or carbon atom to which they are bound, form a 5 to 7-membered heterocyclic ring;
• R6 is H, C1-C12 alkyl, C2-C12 alkenyl or aralkyl;
• R7 is C1-C12 alkyl optionally substituted with hydroxyl or alkoxy;
• and
• wherein each alkyl, alkenyl, alkylene, alkenylene, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, aryl and aralkyl is independently substituted or unsubstituted unless otherwise specified.